دورية أكاديمية
أعرض في EDS

Methodological guidelines and publications of benefit-risk assessment for health technology assessment: a scoping review.

التفاصيل البيبلوغرافية
العنوان: Methodological guidelines and publications of benefit-risk assessment for health technology assessment: a scoping review.
المؤلفون: Suzumura EA; Departamento de Medicina Preventiva, Faculdade de Medicina - FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil esuzumura@yahoo.com.br.; Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT TIROL - University for Health Sciences and Technology, Hall in Tirol, Austria., de Oliveira Ascef B; Departamento de Medicina Preventiva, Faculdade de Medicina - FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil., Maia FHA; Departamento de Medicina Preventiva, Faculdade de Medicina - FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil., Bortoluzzi AFR; Departamento de Medicina Preventiva, Faculdade de Medicina - FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil., Domingues SM; Departamento de Medicina Preventiva, Faculdade de Medicina - FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil., Farias NS; Departamento de Medicina Preventiva, Faculdade de Medicina - FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil., Gabriel FC; Departamento de Ciências Farmacêuticas, Universidade de Sao Paulo, Sao Paulo, SP, Brazil., Jahn B; Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT TIROL - University for Health Sciences and Technology, Hall in Tirol, Austria., Siebert U; Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT TIROL - University for Health Sciences and Technology, Hall in Tirol, Austria.; Division of Health Technology Assessment, ONCOTYROL - Center for Personalized Cancer Medicine, Innsbruck, Austria.; Center for Health Decision Science, Departments of Epidemiology and Health Policy & Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA.; Program on Cardiovascular Research, Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., de Soarez PC; Departamento de Medicina Preventiva, Faculdade de Medicina - FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
المصدر: BMJ open [BMJ Open] 2024 Jun 08; Vol. 14 (6), pp. e086603. Date of Electronic Publication: 2024 Jun 08.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BMJ Publishing Group Ltd, 2011-
مواضيع طبية MeSH: Technology Assessment, Biomedical*/methods, Humans ; Risk Assessment/methods ; Guidelines as Topic ; Brazil
مستخلص: Objectives: To map the available methodological guidelines and documents for conducting and reporting benefit-risk assessment (BRA) during health technologies' life cycle; and to identify methodological guidelines for BRA that could serve as the basis for the development of a BRA guideline for the context of health technology assessment (HTA) in Brazil.
Design: Scoping review.
Methods: Searches were conducted in three main sources up to March 2023: (1) electronic databases; (2) grey literature (48 HTA and regulatory organisations) and (3) manual search and contacting experts. We included methodological guidelines or publications presenting methods for conducting or reporting BRA of any type of health technologies in any context of the technology's life cycle. Selection process and data charting were conducted by independent reviewers. We provided a structured narrative synthesis of the findings.
Results: From the 83 eligible documents, six were produced in the HTA context, 30 in the regulatory and 35 involved guidance for BRA throughout the technology's life cycle. We identified 129 methodological approaches for BRA in the documents. The most commonly referred to descriptive frameworks were the Problem, Objectives, Alternatives, Consequences, Trade-offs, Uncertainty, Risk and Linked decisions and the Benefit-Risk Action Team. Multicriteria decision analysis was the most commonly cited quantitative framework. We also identified the most cited metric indices, estimation and utility survey techniques that could be used for BRA.
Conclusions: Methods for BRA in HTA are less established. The findings of this review, however, will support and inform the elaboration of the Brazilian methodological guideline on BRA for HTA.
Trial Registration Number: https://doi.org/10.17605/OSF.IO/69T3V.
Competing Interests: Competing interests: None declared.
(© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
References: Pharmacoepidemiol Drug Saf. 2015 Dec;24(12):1233-40. (PMID: 26456379)
Ther Innov Regul Sci. 2017 Jul;51(4):501-508. (PMID: 30227054)
Ther Innov Regul Sci. 2017 Sep;51(5):625-634. (PMID: 30231686)
J Crohns Colitis. 2023 Jan 27;17(1):137-143. (PMID: 35952722)
J Biopharm Stat. 2013;23(1):231-8. (PMID: 23331233)
Drug Saf. 2018 Aug;41(8):775-786. (PMID: 29582392)
Hum Vaccin Immunother. 2016;12(1):176-81. (PMID: 26305537)
Food Chem Toxicol. 2012 Jan;50(1):26-32. (PMID: 21683115)
Value Health. 2012 Dec;15(8):1172-81. (PMID: 23244821)
Value Health. 2020 Dec;23(12):1622-1629. (PMID: 33248518)
Ther Innov Regul Sci. 2016 May;50(3):342-346. (PMID: 30227065)
JBI Evid Synth. 2020 Oct;18(10):2119-2126. (PMID: 33038124)
Clin Chem Lab Med. 2022 Mar 03;60(5):647-654. (PMID: 35245972)
Dialogues Clin Neurosci. 2011;13(2):183-90. (PMID: 21842615)
Br J Clin Pharmacol. 2021 Feb;87(2):395-405. (PMID: 32529733)
Drug Saf. 2003;26(12):853-62. (PMID: 12959629)
BMC Med Res Methodol. 2012 Nov 19;12:173. (PMID: 23163976)
Value Health. 2010 Aug;13(5):657-66. (PMID: 20412543)
Med Decis Making. 2009 Jan-Feb;29(1):104-15. (PMID: 18812582)
Rev Saude Publica. 2010 Apr;44(2):381-3. (PMID: 20339641)
Drug Saf. 2020 Nov;43(11):1105-1120. (PMID: 32918682)
J Clin Epidemiol. 2016 Jul;75:40-6. (PMID: 27005575)
Clin Pharmacol Ther. 2011 Feb;89(2):217-24. (PMID: 21178990)
Value Health. 2015 Dec;18(8):1057-62. (PMID: 26686791)
Contemp Clin Trials. 2018 Apr;67:100-108. (PMID: 29505866)
Genet Med. 2010 Nov;12(11):686-93. (PMID: 20808229)
Ther Adv Drug Saf. 2020 Dec 08;11:2042098620976951. (PMID: 33343857)
Ther Innov Regul Sci. 2016 Nov;50(6):718-723. (PMID: 30231743)
Value Health. 2016 Sep - Oct;19(6):746-750. (PMID: 27712701)
Vaccine. 2020 Dec 22;38 Suppl 2:B65-B75. (PMID: 31677947)
Value Health. 2015 Mar;18(2):250-9. (PMID: 25773560)
BMJ Open. 2023 Dec 10;13(12):e075333. (PMID: 38072481)
Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):667-78. (PMID: 24821575)
Ther Innov Regul Sci. 2017 Sep;51(5):635-644. (PMID: 30231684)
Ann Intern Med. 2018 Oct 2;169(7):467-473. (PMID: 30178033)
Pharmacoepidemiol Drug Saf. 2007 Jul;16 Suppl 1:S2-S15. (PMID: 17546573)
Circulation. 2020 Nov 17;142(20):1974-1988. (PMID: 33196311)
Appl Health Econ Health Policy. 2013 Aug;11(4):319-29. (PMID: 23637054)
J Eval Clin Pract. 2017 Feb;23(1):128-138. (PMID: 27762080)
Drug Saf. 2017 Jan;40(1):15-36. (PMID: 27743334)
Pharm Stat. 2016 Jul;15(4):324-32. (PMID: 25981683)
Front Pharmacol. 2014 Dec 04;5:269. (PMID: 25538620)
Drug Discov Today Technol. 2011 Spring;8(1):e1-e42. (PMID: 24103837)
Acad Radiol. 2014 Sep;21(9):1138-43. (PMID: 25107866)
Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):238-50. (PMID: 26521865)
Value Health. 2023 Apr;26(4):449-460. (PMID: 37005055)
Fed Regist. 2016 Jul 19;81(138):46938-40. (PMID: 27459749)
Ther Innov Regul Sci. 2015 Jan;49(1):17-25. (PMID: 30222450)
Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):251-62. (PMID: 26800458)
Br J Clin Pharmacol. 2015 Nov;80(5):979-91. (PMID: 25940398)
Ther Innov Regul Sci. 2016 Jan;50(1):130-134. (PMID: 30236009)
Regul Toxicol Pharmacol. 2020 Mar;111:104546. (PMID: 31830500)
Drug Discov Today Technol. 2011 Spring;8(1):e1-e42. (PMID: 24103841)
Ther Adv Drug Saf. 2019 Aug 26;10:2042098619871180. (PMID: 31489173)
Ther Innov Regul Sci. 2015 May;49(3):425-433. (PMID: 30222397)
Contemp Clin Trials. 2020 Aug;95:106073. (PMID: 32622973)
Drug Saf. 2020 Nov;43(11):1089-1104. (PMID: 32914292)
فهرسة مساهمة: Keywords: health policy; public health; statistics & research methods
تواريخ الأحداث: Date Created: 20240608 Date Completed: 20240608 Latest Revision: 20240617
رمز التحديث: 20240618
مُعرف محوري في PubMed: PMC11163601
DOI: 10.1136/bmjopen-2024-086603
PMID: 38851235
قاعدة البيانات: MEDLINE
الوصف
تدمد:2044-6055
DOI:10.1136/bmjopen-2024-086603